September 14, 2021 + Jessica Di Palo
1 Min read
It all started on the 10th of March of this year, the day on which the ESG – Sustainable Finance Disclosure Regulation (EU) 2919/2088 came into effect. In this blog post, we will be highlighting the differences between the various classifications of assets such as Art. 6, Art. 8, and Art. 9 of the Sustainable Finance Disclosure Regulation (SFDR).
In the last decades, our world and societies have been facing various alarming environmental emergencies. Governments, Politicians, Companies, and even Celebrities are talking about a wide range of raising concerns, often under the premise: “act now!”. The establishment of the Paris Agreement was the very first step towards a universal, legally binding, global climate change agreement at the Paris climate conference in December 2015. The target? To reduce emissions. Precisely: to keep the increase in global average temperature to well below 2°C and to aim to limit the increase to a maximum of 1.5°C. The next step was to set up the 2030 Agenda for Sustainable Development. As a “plan of action for people, planet and prosperity” the agenda 2030 aims with 17 Sustainable Development Goals (SDGs) to “strengthen universal peace in larger freedom”.
In the investment sector, we have been using environmental, social and governance (ESG) characteristics to evaluate potential portfolio companies to achieve the target of more sustainable investments. For the financial sector, a new regulation was put into action in 2021 – the Sustainable Finance Disclosure (SFDR). Starting from March 10th the SFDR sets out sustainability disclosure requirements for different participants of the financial market, advisers, and financial products. The regulation focuses on foreseen metrics for evaluating ESG outcomes of any given investment procedure. The goal here is to disclose, as the regulation clearly states in its name. A variety of rules are placed to make sure that any harmful impact by investee companies gets identified.
At MTIP we acted and ratified the regulations early on. Furthermore, we are fully compliant with Article 9 of the regulations. But what does this even mean? SFDR brings one important set of rules to the table, to classify mandates and funds into three distinctive categories.
We will have a closer look at Art. 6, Art.8, and Art. 9 of the regulation:
Article 6: Transparency of the integration of sustainability risks
Article 6 covers funds that do not promote themselves as being sustainable. This means that these types of funds do not integrate ESG factors and objectives into their strategy or investment process. No major changes occurred after the SFDR was established, meaning that these types of companies can continue with their business in the EU if they label themselves as non-sustainable. Given that SFDR regulations are getting more and more attention from institutional investors, these types of funds will certainly face difficult times in marketing their funds in the future.
Article 8: Transparency of the promotion of environmental or social characteristics in pre-contractual disclosures
Article 8 Funds are referred to as “Light Green Funds” and must meet the two following requirements:
Article 9: Transparency of sustainable investments in pre-contractual disclosures
Finally, SFDR Article 9 defines “Dark Green Funds”. We focus here on the product itself, namely the fund. Let’s take a closer look at the article. There are three distinctions of dark green funds, as we can see in the regulation.
(a) information on how the designated index is aligned with that objective;
(b) an explanation as to why and how the designated index aligned with that objective differs from a broad market index.
The first two (1 + 2) set out that the fund itself has sustainable investments as its target. The distinction between the two lies in the fact of whether there is an index that was established as a reference or not. The last one (3) focuses on the reduction of carbon emissions.
Dark green funds are currently the highest classification of sustainable investments a European fund can achieve. We are extremely proud that our MTIP Fund two is one of the first funds to get this qualification. Experts argue that most European funds might only reach the SFDR Article 8 status as a “light green fund”.
Diversity, Equity, and Inclusion: The 3 Key Drivers for Success
We have talked with Caroline Noublanche, CEO of our portfolio company Apricity, about her company’s DEI efforts.
Growth Capital Decisions – An Interview with our Co-Founder & Managing Partner Dr. Christoph Kausch
Growth Capital Decisions
Rahel Hafner Receives Certificate in ESG Investing by CFA Institute
Rahel Hafner Receives Certificate in ESG Investing
What Makes a Great Founder/Investor Relationship?
Interview with the CEO and Co-Founder Kai Eberhardt of our portfolio company Oviva
MTIP’s HealthCare Clinic 2022
This year's HealthCare Clinic was held under the motto: "Surfing the Healthtech Waves of Change".
Christoph Kausch selected by Real Deals as most influential for 2022
Christoph Kausch named by Real Deals most influential for 2022
MTIP leads €17 million financing round in virtual fertility clinic Apricity
New MTIP investment
MTIP leads the €20 million growth financing round in LynxCare
Largest capital round ever in digital health in Belgium
Pioneering the use of machine learning algorithms to turbo-charge drug development
Intelligencia revolutionizes drug development
The psychology of decision making
What makes a good investor?
Revolutionizing medical triage with artificial intelligence
Mediktor's solution for medical triage
MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments
MTIP Fund II is closed!
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
MTIP invests in Mediktor
New investment in Mediktor
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
Oviva raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Private Equity 101: Part one – Glossary
Are you new to the healthtech space?
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health